Healthcare Industry News: antibiotic
News Release - August 17, 2016
ProclaRx Names Doug Martin as Chief Operating OfficerCOLUMBUS, Ohio, Aug. 17, 2016 -- (Healthcare Sales & Marketing Network) -- ProclaRx, a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections, today announced the appointment of Doug Martin as the new Chief Operating Officer (COO) of ProclaRx, effective immediately.
Martin brings more than 20 years of extensive legal and business experience to his new executive role at ProclaRx. As COO, Martin will be responsible for the strategic planning, compliance, and coordination of R&D resources. He will report directly to Nick Henderson, Chairman of the Board at ProclaRx.
"We are extremely pleased to have someone with Doug's extensive background and experience join ProclaRx as we continue to accelerate the development of our anti-biofilm technology," said Nick Henderson, Chairman of the Board, ProclaRx. "His intimate knowledge of how complex, multibillion dollar corporations function gives Doug the skill portfolio needed to drive our company forward. Additionally, in his prior role as Strategic Advisor to ProclaRx, we have seen the energy and insight Doug brings to the company, which makes us very confident in our decision to bring him on board as COO."
Prior to becoming COO of ProclaRx, Martin was responsible for developing and implementing corporate structures needed to effectively fund the acquisition and development of bio-pharma IP as the Director of Corporate Strategy at Applied Bio Ventures. The company's primary objective is to commercialize "best-in-class" drugs and devices for license or sale. Before Applied Bio Ventures, Martin served as the Vice President and Assistant General Counsel of Regulatory Legal and Government Relations at the Fireman's Fund Insurance Company within Allianz Global Corporate & Specialty (AGCS). In that role, he led a highly experienced team of lawyers, regulatory specialists, and paralegals, and was responsible for advising and jointly solving business, legal, and regulatory issues. Martin held a number of senior executive positions, including Vice President and Senior Counsel of Government Relations, over the course of his 19 years at AGCS.
"I am honored to join the ProclaRx team of experienced scientists, researchers, and drug commercialization experts whose singular vision is to efficiently and effectively help children and adults with chronic and intractable infections," said Doug Martin, Chief Operating Office, ProclaRx. "The ProclaRx anti-biofilm technology represents a profound, new approach to addressing bacterial infections, which includes the reduction of antibiotic use while clearing infections. To prolong the useful life of antibiotics, the medical community needs a disruptive approach to the attack on infections. This anti-biofilm technology is that disruptive answer."
Martin serves on the Board of Directors at Marin School to Career Partnership (Student Internships) and California Conservation Corps Foundation, and is an active member of the State Bar of California. He earned a bachelor's degree in literature from San Francisco State University, and acquired his Doctor of Law degree (J.D.) from San Francisco Law School.
Established in 2014, ProclaRx and its staff of experienced scientists are committed to eliminating the causes of countless chronic and recurrent human infections. The Columbus-based company prides itself on developing and commercializing anti-infective technologies, with the goal of eliminating biofilms and helping cure diseases. With $6.5 million invested to-date, ProclaRx is seeking additional strategic partners to help further its continued efforts to develop multiple innovative therapeutics for patients suffering from serious bacterial infections.
To learn more about ProclaRx, please visit www.proclarx.com. If you are interested in supporting ProclaRx's efforts, please contact Nick Henderson for more information at firstname.lastname@example.org.
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, chronic suppurative otitis media, and CVID sinusitis. Visit www.proclarx.com, call 949-302-2165, or email email@example.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.